CommercialPrior AuthMedium impact
Cosibelimab-ipdl (Unloxcyt) (CPB 1074, reviewed 2026-03-25)
Aetna·Dermatology, Oncology, General Surgery·Medical Policy
Effective date
Mar 14, 2025
We identified it
Aug 12, 2026
Summary
Aetna has established a new medical policy for cosibelimab-ipdl (Unloxcyt), a PD-L1 blocking antibody approved for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients not candidates for curative surgery or radiation. The policy requires precertification for all commercial plans, specifies approved billing codes (J9275, 96413, 96415), and limits coverage to CSCC only—all other indications are considered experimental. Billing teams must implement prior authorization requirements and ensure proper diagnosis coding before claims submission.
Action Required
Before March 14, 2025: (1) Billing team must update systems to require precertification for all HCPCS code J9275 (cosibelimab-ipdl) claims on Aetna commercial plans. (2) Establish precertification process: contact (866) 752-7021 or fax (888) 267-3277 with Statement of Medical Necessity forms before claim submission. (3) Update diagnosis coding rules to allow only ICD-10 codes C44.02 through C44.92 (cutaneous squamous cell carcinoma) for coverage; flag claims with other diagnoses for manual review and denial. (4) Add site-of-care review requirement per Aetna's Utilization Management Policy on specialty drug infusions. (5) Providers must document that patient is not a candidate for curative surgery or radiation in medical record before treatment. (6) Train front-desk staff to initiate precertification requests at scheduling; educate providers that claims without prior authorization will be denied. Failure to implement precertification will result in claim denials.